Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Gastric cancer associated WDR5 and KAT2A binding long non-coding RNA (GCAWKR)
- Target
- GCAWKR
- Molecular classification
- Long non-coding RNA (lncRNA), Molecular scaffold, Chromatin modifier binding partner
01
Overview
Gastric cancer associated WDR5 and KAT2A binding lncRNA (GCAWKR) is a long non-coding RNA (lncRNA) highly upregulated in gastric cancer tissues[1][5]. GCAWKR promotes gastric tumorigenesis by serving as a molecular scaffold for two chromatin-modifying proteins, WDR5 and KAT2A, enhancing their co-localization at target gene promoters and increasing oncogenic histone modifications. Functionally, GCAWKR drives cell proliferation and invasion in multiple gastric cancer models and its expression correlates with poor clinical outcomes, including increased tumor size, metastasis, and advanced disease stage[1][7]. It represents a potential therapeutic biomarker and target for novel anti-cancer strategies focused on disrupting pro-tumorigenic chromatin complexes[1][5][7].
02
Mechanism of action
Not directly applicable as a drug target yet; mechanistically, it promotes carcinogenesis by scaffolding WDR5/KAT2A and facilitating active chromatin marks at oncogenic promoters
03
Biological functions
Acts as a scaffold for WDR5 and KAT2A complexesModulates chromatin modifications on target gene promotersRegulates cell proliferationRegulates cell invasion
04
Disease associations
Cancer (specifically, gastric cancer)
05
Safety considerations
As GCAWKR itself is not yet a clinical drug target, direct safety concerns are not reported; however, targeting lncRNAs may risk off-target effects or disruption of normal epigenetic homeostasis.
06
Biomarkers
High GCAWKR levels are correlated with poor prognosis, larger tumor size, lymph node metastasis, and advanced TNM stage in gastric cancer
Beyond the preview
Go deeper on Gastric cancer associated WDR5 and KAT2A binding long non-coding RNA (GCAWKR).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gastric cancer associated WDR5 and KAT2A binding long non-coding RNA (GCAWKR).